Concordance of DMET Plus Genotyping Results With Those of Orthogonal Genotyping Methods

被引：34

作者：

Fernandez, C. A. ^{[2
]}

Smith, C. ^{[2
]}

Yang, W. ^{[2
]}

Lorier, R. ^{[1
]}

Crews, K. R. ^{[2
]}

Kornegay, N. ^{[2
]}

Hicks, J. K. ^{[2
]}

Stewart, C. F. ^{[2
]}

Kawedia, J. D. ^{[2
]}

Ramsey, L. B. ^{[2
]}

Liu, C. ^{[2
]}

Evans, W. E. ^{[2
]}

Relling, M. V. ^{[2
]}

Broeckel, U. ^{[1
]}

机构：

[1] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA

[2] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2012年 / 92卷 / 03期

基金：

美国国家卫生研究院;

关键词：

PHARMACOGENOMICS; POLYMORPHISMS; VARIANTS; CRHR1;

D O I：

10.1038/clpt.2012.95

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

There are several hurdles to the clinical implementation of pharmacogenetics. One approach is to employ pre-prescription genotyping, involving interrogation of multiple pharmacogenetic variants using a high-throughput platform. We compared the performance of the Drug Metabolizing Enzymes and Transporters (DMET) Plus array (1,931 variants in 225 genes) with that of orthogonal genotyping methods in 220 pediatric patients. A total of 1,692 variants had call rates >98% and were in Hardy-Weinberg equilibrium. Of these, 259 were genotyped by at least one independent method, and a total of 19,942 single-nucleotide polymorphism (SNP)-patient sample pairs were evaluated. The concordance rate was 99.9%, with only 28 genotype discordances observed. For the genes deemed most likely to be clinically relevant (TPMT, CYP2D6, CYP2C19, CYP2C9, VKORC1, DPYD, UGT1A1, and SLCO1B1), a total of 3,799 SNP-patient sample pairs were evaluable and had a concordance rate of 99.96%. We conclude that the DMET Plus array performs well with primary patient samples, with the results in good concordance with those of several lower-throughput genotyping methods.

引用

页码：360 / 365

页数：6

共 21 条

[1]

Affymetrix, 2011, DMET PLUS GEN COP NU

[2]

Affymetrix, 2011, DMET PLUS PREM PACK

[3]

Burmester JK, 2010, METHODS MOL BIOL, V632, P99, DOI 10.1007/978-1-60761-663-4_7

[4] Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport [J].

Daly, Thomas M. ;

Dumaual, Carmen M. ;

Miao, Xin ;

Farmen, Mark W. ;

Njau, Reuben K. ;

Fu, Dong-Jing ;

Bauer, Nancy L. ;

Close, Sandra ;

Watanabe, Nancy ;

Bruckner, Carsten ;

Hardenbol, Paul ;

Hockett, Richard D. .

CLINICAL CHEMISTRY, 2007, 53 (07) :1222-1230

[5] A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform [J].

Deeken, J. F. ;

Cormier, T. ;

Price, D. K. ;

Sissung, T. M. ;

Steinberg, S. M. ;

Tran, K. ;

Liewehr, D. J. ;

Dahut, W. L. ;

Miao, X. ;

Figg, W. D. .

PHARMACOGENOMICS JOURNAL, 2010, 10 (03) :191-199

[6]

Deeken J, 2009, CURR OPIN MOL THER, V11, P260

[7] Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications [J].

Dervieux, T ;

Meshkin, B ;

Neri, B .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2005, 573 (1-2) :180-194

[8] Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix® Targeted Genotyping System [J].

Dumaual, Carmen ;

Miao, Xin ;

Daly, Thomas M. ;

Bruckner, Carsten ;

Njau, Reuben ;

Fu, Dong-Jing ;

Close-Kirkwood, Sandra ;

Bauer, Nancy ;

Watanabe, Nancy ;

Hardenbol, Paul ;

Hockett, Richard D. .

PHARMACOGENOMICS, 2007, 8 (03) :293-305

[9] Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects [J].

Evans, WE ;

McLeod, HL .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) :538-549

[10] A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia:: a report from the Children's Oncology Group [J].

French, Deborah ;

Hamilton, Leo H. ;

Mattano, Leonard A., Jr. ;

Sather, Harland N. ;

Devidas, Meenakshi ;

Nachman, James B. ;

Relling, Mary V. .

BLOOD, 2008, 111 (09) :4496-4499

← 1 2 3 →